Barclays
LEGN icon

Barclays’s Legend Biotech LEGN Stock Holding History

Barclays’s Portfolio LEGN Stock Details LEGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-14,200
Closed -$796K – 5116
2024
Q1 		$796K Buy
+14,200
New +$856K ﹤0.01% 3294
2023
Q1 		– Sell
-30,000
Closed -$1.5M – 5227
2022
Q4 		$1.5M Buy
+30,000
New +$1.45M ﹤0.01% 2468

Other funds holding LEGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
FBIL
First Beijing Investment Ltd Hong Kong $2.32B AUM 8.06% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Barclays's LEGN Position: Q1 2026 in Review

Barclays reduced its Legend Biotech (LEGN) stake by 34% in Q1 2026, selling an estimated $1.79M and leaving 179,900 shares worth $3.25M. The position accounts for ﹤0.01% of the portfolio, ranked #2075.

Barclays first reported a position in LEGN in Q1 2022 and has held it in 17 quarters since. The position peaked at $23.6M in Q4 2022. 190 funds tracked by Wall St. Rank hold LEGN as of Q1 2026.

  • Barclays held 179,900 shares of Legend Biotech worth $3.25M as of Q1 2026.
  • Barclays sold 93,920 Legend Biotech shares in Q1 2026, an estimated $1.79M.
  • Legend Biotech made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #2075 holding.
  • Barclays first reported a position in Legend Biotech in Q1 2022 and has held it in 17 quarters since.
  • Barclays's Legend Biotech position peaked at $23.6M in Q4 2022.
  • 190 funds tracked by Wall St. Rank held Legend Biotech as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.